低悪性度リンパ腫:世界の臨床試験レビュー(2014年上半期)...市場調査レポートについてご紹介

【英文タイトル】Indolent Lymphoma Global Clinical Trials Review, H1, 2014

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Indolent Lymphoma 6
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Indolent Lymphoma to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Unaccomplished Trials of Indolent Lymphoma 25
Subjects Recruited Over a Period of Time 27
Clinical Trials by Sponsor Type 28
Prominent Sponsors 29
Top Companies Participating in Indolent Lymphoma Therapeutics Clinical Trials 30
Prominent Drugs 31
Latest Clinical Trials News on Indolent Lymphoma 32
Jan 22, 2014: New drug shows promise in treating indolent non-Hodgkin lymphomas 32
Dec 10, 2013: Studies Evaluating REVLIMID (Lenalidomide) in Lymphoma Presented at ASH 32
Dec 08, 2013: Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma 34
Dec 10, 2012: Infinity Pharma Reports IPI-145 Phase I Data Showing Clinical Activity In B-Cell And T-Cell Malignancies At ASH Annual Meeting 35
Aug 17, 2011: Emergent Announces Initiation Of Phase Ib/II Study Of TRU-016 In Combination With Rituximab And Bendamustine In Subjects With Relapsed-Indolent Lymphoma 36
Clinical Trial Profiles 38
Clinical Trial Overview of Top Companies 38
F. Hoffmann-La Roche Ltd. 38
Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 38
Gilead Sciences, Inc. 40
Clinical Trial Overview of Gilead Sciences, Inc. 40
Celgene Corporation 41
Clinical Trial Overview of Celgene Corporation 41
Teva Pharmaceutical Industries Limited 42
Clinical Trial Overview of Teva Pharmaceutical Industries Limited 42
Cell Therapeutics, Inc. 43
Clinical Trial Overview of Cell Therapeutics, Inc. 43
GlaxoSmithKline plc 44
Clinical Trial Overview of GlaxoSmithKline plc 44
Sanofi 45
Clinical Trial Overview of Sanofi 45
Pharmacyclics, Inc. 46
Clinical Trial Overview of Pharmacyclics, Inc. 46
Infinity Pharmaceuticals, Inc. 47
Clinical Trial Overview of Infinity Pharmaceuticals, Inc. 47
Bayer AG 48
Clinical Trial Overview of Bayer AG 48
Clinical Trial Overview of Top Institutes / Government 49
National Cancer Institute 49
Clinical Trial Overview of National Cancer Institute 49
The University of Texas M. D. Anderson Cancer Center 50
Clinical Trial Overview of The University of Texas M. D. Anderson Cancer Center 50
Memorial Sloan Kettering Cancer Center 51
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 51
University of Nebraska 52
Clinical Trial Overview of University of Nebraska 52
Fred Hutchinson Cancer Research Center 53
Clinical Trial Overview of Fred Hutchinson Cancer Research Center 53
Hoag Memorial Hospital Presbyterian 54
Clinical Trial Overview of Hoag Memorial Hospital Presbyterian 54
Massachusetts General Hospital 55
Clinical Trial Overview of Massachusetts General Hospital 55
Beth Israel Deaconess Medical Center 56
Clinical Trial Overview of Beth Israel Deaconess Medical Center 56
Virginia Commonwealth University 57
Clinical Trial Overview of Virginia Commonwealth University 57
Ohio State University Comprehensive Cancer Center 58
Clinical Trial Overview of Ohio State University Comprehensive Cancer Center 58
Five Key Clinical Profiles 59
Appendix 151
Abbreviations 151
Definitions 151
Research Methodology 152
Secondary Research 152
About GlobalData 153
Contact Us 153
Disclaimer 153
Source 154


【レポート販売概要】

■ タイトル:低悪性度リンパ腫:世界の臨床試験レビュー(2014年上半期)
■ 英文:Indolent Lymphoma Global Clinical Trials Review, H1, 2014
■ 発行日:2014年2月28日
■ 調査会社:GlobalData
■ 商品コード:GDHC2020CTIDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。